ストックスクリーナーアプリを入手
17.47
1.36%
-0.24
アフターアワーズ：
17.92
0.45
+2.58%
前日終値:
$17.71
開ける：
$17.9
24時間の取引高:
1.05M
Relative Volume:
0.51
時価総額：
$2.89B
収益：
-
当期純損益:
$-446.21M
株価収益率:
-4.9303
EPS:
-3.5434
ネットキャッシュフロー:
$-423.92M
1週間 パフォーマンス:
-3.80%
1か月 パフォーマンス:
-7.27%
6か月 パフォーマンス:
-16.41%
1年 パフォーマンス:
+47.68%
1日の値動き範囲:
$16.97
$18.13
1週間の範囲:
$16.97
$18.13
52週間の値動き範囲:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.47 | 2.93B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-10-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-25 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
MSN Money - MSN
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Wall Street Zen Downgrades Dyne Therapeutics (NASDAQ:DYN) to Strong Sell - MarketBeat
Understanding the Setup: (DYN) and Scalable Risk - Stock Traders Daily
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 227,337 Shares of Stock - MarketBeat
Dyne therapeutics director Jason Rhodes sells $4.18m in stock By Investing.com - Investing.com Australia
Dyne therapeutics director Jason Rhodes sells $4.18m in stock - Investing.com
Dyne Therapeutics(DYN.US) Director Sells US$4.18 Million in Common Stock - Moomoo
Dyne Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Rhodes Jason P - Moomoo
Atlas Venture funds tied to Dyne (DYN) director sell 227,337 shares - Stock Titan
Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise? - simplywall.st
Dyne Therapeutics earnings up next: DMD launch path in focus By Investing.com - Investing.com India
Dyne Therapeutics earnings up next: DMD launch path in focus - Investing.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
Dyne Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Dyne Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Lubner David Charles - Moomoo
Director at Dyne Therapeutics (DYN) makes bona fide gift of 53,625 shares - Stock Titan
Dyne Therapeutics Insider Sold Shares Worth $7,101,120, According to a Recent SEC Filing - marketscreener.com
Dyne therapeutics director Jason Rhodes sells $7.1m in stock By Investing.com - Investing.com South Africa
Dyne Therapeutics (NASDAQ:DYN) Director Sells $3,148,897.95 in Stock - MarketBeat
Dyne Therapeutics(DYN.US) Director Sells US$7.1 Million in Common Stock - Moomoo
Dyne therapeutics director Jason Rhodes sells $7.1m in stock - Investing.com
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - The Manila Times
Dyne Therapeutics Announces Upcoming Presentation - GlobeNewswire
Dyne to show primate data on crossing the blood-brain barrier - Stock Titan
Dyne Therapeutics (DYN) Stifel 2026 Virtual CNS Forum Summary - Quartr
Dyne Therapeutics (DYN) Proxy filing Summary - Quartr
Dyne Therapeutics (DYN) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Dyne Therapeutics director Kersten sells $219k in company stock - Investing.com
Dyne Therapeutics director Kersten sells $219k in company stock By Investing.com - Investing.com India
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
[ARS] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Director-affiliated fund trims Dyne Therapeutics (DYN) stake in 10b5-1 sales - Stock Titan
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):